The McGill click-clotting cytogel work, published in Nature on April 29, continues to carry into May's trauma-medicine conference cycle. [1] The method — bio-orthogonal cross-linking of red-blood-cell surface proteins into a hemostatic gel within five seconds — produces a clot that the paper measures as thirteen times more fracture-resistant and four times more adhesive than a natural one. The autologous preparation, from a patient's own blood, takes roughly twenty minutes. The allogeneic preparation, from type-matched donor blood, takes about ten. [2]

The paper's Sunday brief on the rodent-liver step framed the structural question as one of prep-time geometry rather than chemistry. Day-after, the institutional reading is the same. The autologous-versus-allogeneic split decides whether the cytogel enters the trauma pipeline as a hospital-bay device or as a pre-hospital one. Twenty minutes is longer than the field-medic window a non-compressible torso wound demands; ten minutes is still longer than most front-line medics will accept. The realistic first deployment is therefore non-compressible internal bleeding in a hospital trauma bay rather than the battlefield. [3]

The May Advanced Trauma Life Support track conferences will carry the question forward into the regulatory grammar. McGill's release names trauma, surgical anti-adhesion, chronic wounds, hemophilia, and von Willebrand disease as the candidate indications. The first three move through the FDA's hemostatic-device clearance pathway; the last two require an investigational-new-drug submission. The next bar is the large-animal model — typically swine for hemorrhagic-shock studies — and a first human trial after that.

The chemistry works. The deployment geometry is the next two years' question.

-- KENJI NAKAMURA, Tokyo